Tag - CALA

Developments

HCW ups Calithera to buy on steady progress of clinical programs

H.C. Wainwright upgraded Calithera Biosciences (NASDAQ:CALA) to “buy” from “neutral” with a 12-month price target of $8, citing two ongoing clinical development programs that are expected to provide data updates in the...

August 29, 2022

Markets

SVB Leerink ups Calithera to OP from MP; PT to $3 from $1

SVB Leerink upgraded Calithera Biosciences (NASDAQ:CALA) to “outperform” from “market perform” and raised its price target to $3 from $1. The stock closed at 49 cents on Jan. 19. “We conducted a deeper dive on...

January 20, 2022

Developments

Calithera treats first patient in Phase 2 non-small cell lung cancer trial

Calithera Biosciences (NASDAQ:CALA) treated the first non-small cell lung cancer (NSCLC) patient in its Phase 2 trial evaluating telaglenastat, a glutaminase inhibitor. The trial will enroll some 120 patients with stage...

September 24, 2020

Markets

HCW starts Calithera Biosciences at buy; PT $7

H.C. Wainwright launched coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $7 price target. The stock closed at $3.38 on Nov. 18. Calithera is developing therapies that target cellular metabolic...

November 19, 2019

Tag - CALA

HCW ups Calithera to buy on steady progress of clinical programs

SVB Leerink ups Calithera to OP from MP; PT to $3 from $1

Calithera treats first patient in Phase 2 non-small cell lung cancer trial

HCW starts Calithera Biosciences at buy; PT $7

General

More